Authors : Dr. Yashodhan Chaughule; Dr. Lakshmi Narayana; Dr. Saravanakumar Kuppusamy; Dr. Manikandan P.

Volume/Issue : Volume 11 - 2026, Issue 7 - July

Google Scholar : https://tinyurl.com/2r7zf99p

Scribd : https://tinyurl.com/4ps3av73

DOI : https://doi.org/10.38124/ijisrt/26jul893

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Fatigue, dyspnea, and impaired quality of life (QoL) are among the most commonly reported symptoms in cancer patients. These symptoms can significantly impact functional independence, emotional well-being, and treatment outcomes. Identifying the prevalence of these symptoms can guide more effective supportive care and rehabilitation strategies.  Aim: To determine the prevalence of fatigue and dyspnea and its association with health releated quality of life among various types of cancer patients.  Materials and Methods: An Analytical cross-sectional study was conducted involving 205 cancer patients, including individuals diagnosed with lung, breast, oral cavity, liver, prostate, thyroid, and other cancers. Participants were assessed using standardized tools: fatigue was evaluated using the Brief Fatigue Inventory Scale, dyspnea was measured with the Modified Medical Research Council (mMRC) Dyspnea Scale, and quality of life was assessed using the EORTC QLQ-C30 questionnaire. Data were analyzed to determine the overall cancer-type-specific prevalence of fatigue, dyspnea and impaired quality of life.

Keywords : Fatigue, Dyspnea, Quality of Life, Cancer, Prevalence, EORTC QLQ- C30, BFI, mMRC.

References :

1. GLOBOCAN 2024 (2024). Global Cancer Observatory. International Agency for Research on Cancer.
2. Indian Council of Medical Research–National Centre for Disease Informatics and Research (ICMR-NCDIR). (2024). National Cancer Registry Programme Report 2024.
3. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2016.
5. Bray, F., Laversanne, M., Weiderpass, E., & Soerjomataram, I. (2021). The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 127(16), 3029–3030.
6. Bower, J. E., Bak, K., Berger, A., Breitbart, W., Escalante, C. P., Ganz, P. A., … & National Comprehensive Cancer Network. (2014). Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. Journal of Clinical Oncology, 32(17), 1840–1850.
7. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2024). Global Cancer Statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(2), 101–132.
8. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609.
9. Ripamonti CI, Bruera E. Dyspnea in cancer patients: pathophysiology and treatment. Support Care Cancer. 2011;19(5):733–746.
10. Aaronson NK, Ahmedzai S, Bergman B, et al. The EORTC QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376.
11. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival. Lancet Oncol. 2009;10(9):865–871.
12. Rajpal S, Kumar A, Joe W. Economic burden of cancer in India: Evidence from national sample survey, 2014. PLoS One. 2018;13(2):e0193320.
13. Mock V, Atkinson A, Barsevick A, et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park). 2000;14(11A):151–61.
14. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients. Oncologist. 2000;5(5):353–60.
15. Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer survivors. Cancer. 2012;118(S8):2261–9.
16. Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer. 1998;34(11):1670–6.
17. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85(5):1186–96.
18. Lawrence DP, Kupelnick B, Miller K, et al. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;(32):40–50.
19. Booth S, Moosavi SH, Higginson IJ. The etiology and management of intractable breathlessness in patients with advanced cancer. J Support Oncol. 2003;1(6):507–12.
20. Wilcock A, Crosby V, Hussain SA, et al. Breathlessness and physiological function in inoperable non-small cell lung cancer. Thorax. 2002;57(5):412–6.
21. Bruera E, Schmitz B, Pither J, et al. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage. 2000;19(5):357–62.
22. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–6.
23. Aaronson NK, Ahmedzai S, Bergman B, et al. The EORTC QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
24. Cella D, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation. J Clin Oncol. 1993;11(3):570–9.
25. Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer. 2001;31(2-3):233–40.
26. Murphy BA, Gilbert J, Ridner SH. Systemic and global toxicities of head and neck treatment. Expert Rev Anticancer Ther. 2007;7(8):1043–53.